Orforglipron vs Tirzepatide: Pill or Shot?

A Pill Versus a Shot — And Why That Framing Matters

The comparison people actually want is simple to state and harder to answer honestly: orforglipron is a once-daily tablet, tirzepatide is a once-weekly injection, and the question is what the pill gives up for that convenience. The short version is that trials point to a real efficacy gap in tirzepatide's favor on both weight and blood sugar — but orforglipron's oral route and manufacturing profile are genuine advantages that the weight-loss number alone does not capture.

This article puts the published trial data side by side: mechanism, weight loss, A1c reduction, and the side-effect profiles. One caveat frames everything below. No trial has compared these two compounds head-to-head. Every number here comes from separate studies run in different populations over different designs, so the differences are cross-trial signals, not measured margins between the two drugs.

Research-context information only. Orforglipron and tirzepatide are active ingredients in FDA-approved medications for chronic weight management (tirzepatide is also approved for type 2 diabetes); research-chemical and compounded forms are not FDA-approved and are sold for research purposes only. Protocols, doses, and reactions reported below come from published clinical trials and community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.

Quick Comparison

Mechanism: One Receptor vs Two, Oral vs Injected

The two differ on two axes at once — how many receptors they hit, and how they get into the body.

Orforglipron — oral, single-receptor

Orforglipron is a non-peptide small molecule that activates the GLP-1 receptor alone. Because it is a synthesized small molecule rather than a peptide, it survives oral dosing well enough to be taken as a tablet. Published pharmacology describes oral bioavailability in the range of 30-40% and a half-life long enough (roughly 24-38 hours) to support once-daily dosing, and its trials used it with no food or water timing restriction. Being non-peptide, it is expected not to be immunogenic, and it carries no reconstitution or injection step.

That small-molecule chemistry is also the source of its most-discussed structural advantage: it is chemically synthesized without the cold-chain and injectable-fill constraints of a peptide, which is why it is often described as more scalable to manufacture.

Tirzepatide — injected, dual-receptor

Tirzepatide activates two incretin receptors, GLP-1 and GIP:

• GLP-1 receptor — appetite suppression, slowed gastric emptying, improved insulin response
• GIP receptor — a second incretin pathway layered on top

Trials of dual GLP-1/GIP agonism have reported larger weight-loss figures than trials of single GLP-1 agonists, and that second receptor is the mechanistic reason usually given for the efficacy gap in the table above. The tradeoff is route: tirzepatide is a peptide delivered by weekly subcutaneous injection, and the research-compound form requires reconstitution before use.

Weight Loss: What the Trials Reported

Both compounds were tested at 72 weeks, which makes the durations comparable even though the trials, populations, and endpoints were not.

Orforglipron — ATTAIN-1

ATTAIN-1 enrolled 3,127 adults with obesity (no diabetes required) over 72 weeks. On the efficacy estimand:

• 36 mg: 12.4% weight loss (about 27.3 lb) versus 0.9% on placebo
• 12 mg: 9.3%
• 6 mg: 7.8%
• Responders at 36 mg: 59.6% reached at least 10% loss; 39.6% reached at least 15%

Tirzepatide — SURMOUNT-1

SURMOUNT-1 studied tirzepatide over 72 weeks in adults with obesity and reported, at the top dose:

• 15 mg: 20.9-22.5% weight loss
• The trial documented substantial proportions of participants reaching 20% and 25% loss thresholds at the higher doses

Reading the gap honestly

Placed next to each other, tirzepatide's 20.9-22.5% is close to double orforglipron's 12.4%. That ordering is consistent with mechanism — a dual GLP-1/GIP agonist against a single GLP-1 agonist — and with the broader pattern across this drug class, where adding receptors has tracked with more weight loss.

But the figures come from different trials with different participants, so the specific spread should be read as a directional signal, not a like-for-like margin. What the data supports saying is narrow and defensible: in its own pivotal trial, tirzepatide reported a substantially larger weight-loss figure than orforglipron reported in its own pivotal trial. Orforglipron's countervailing advantage is not on the weight number — it is that the 12.4% was achieved with a daily pill rather than a weekly injection.

Blood Sugar: A1c Reduction

The same ordering shows up in the diabetes data.

• Orforglipron: ACHIEVE-1 (early type 2 diabetes, 40 weeks, baseline A1c 8.0%) reported A1c reductions of about 1.6% at 12 mg and 1.5% at 36 mg. ATTAIN-2, in adults with obesity and type 2 diabetes, reported roughly 1.8% at 36 mg, with 75% of that arm reaching an A1c at or below 6.5%.
• Tirzepatide: SURPASS-2 reported an A1c reduction of about 2.30% on the 15 mg dose.

Again the caveat holds — separate trials, different populations — but the pattern is the same as the weight data: tirzepatide's reported reduction is larger, and orforglipron's reported reduction is meaningful but lower, consistent with single- versus dual-receptor activity.

Side Effects: Both GI-Dominant

Both compounds are dominated by gastrointestinal effects that trials describe as dose-dependent and concentrated during dose escalation.

Orforglipron's ATTAIN-1 reported, at 36 mg versus placebo:

Adverse-event discontinuation in ATTAIN-1 rose with dose, reaching about 10.3% at 36 mg against 2.6% on placebo. On laboratory safety, the orforglipron trials to date have not reported a clinically meaningful liver-enzyme signal, and no pancreatitis, retinal, or optic-neuropathy signal has emerged so far, with post-approval monitoring ongoing.

Tirzepatide's trial record shows the same GI-led pattern that the GLP-1 class produces. Because no head-to-head trial has been run, the two tolerability profiles cannot be ranked against each other from a single study — what can be said is that both are driven by the same GLP-1-mediated GI effects, and both are described as heaviest during titration.

For the compound-specific breakdowns, see Tirzepatide Side Effects.

Cost, Access, and the Oral Advantage

The weight-loss table favors tirzepatide, but the route is where orforglipron's case sits, and it is a real one. A daily oral tablet removes reconstitution, injection, needle handling, and the refrigeration a peptide typically needs. Orforglipron's small-molecule chemistry is also easier to manufacture at scale than an injectable peptide — a supply-side point that matters for a drug class that has repeatedly run into shortages.

Tirzepatide's advantage is depth of evidence and availability in the research market. It is widely stocked across the vendors we track, with an extensive published trial record behind it and approval for both type 2 diabetes and chronic weight management.

For current tirzepatide pricing across vendors, see the tirzepatide cost comparison and live prices pages.

The Verdict, By Priority

There is no single winner — the two optimize for different things, and the trial data draws the line cleanly.

The honest summary: if the deciding factor is how much weight or how much A1c a compound moved in its trials, tirzepatide reported more on both. If the deciding factor is avoiding injections — or a preference for an oral option that is easier to scale and store — that is orforglipron's entire reason to exist, and it delivers it. What the evidence does not support is treating the pill as an equivalent swap for the injection; on the efficacy numbers reported so far, it is a different tradeoff, not a like-for-like substitute.